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Abstract: 
 
Background: Increased levels of histamine have been previously demonstrated in patients with 
chronic idiopathic urticaria. Objective: The purpose of the study was to determine whether 
increased numbers of mast cells are present in lesional skin from such patients. Methods: Mast 
cells have been quantified in lesional (n = 11) and nonlesional (n = 9) skin from patients 
with chronic idiopathic urticaria and compared with site-matched skin from healthy control 
subjects (n = 10). Mast cells were identified by using a sensitive, double-labeling 
immunohistochemical technique with specific monoclonal antibodies to mast cell 
tryptase and chymaseand quantified under light microscopy. Results: No significant differences 
in mast cell numbers from lesional, nonlesional, or control skin were observed (p > 0.1, 
Student's t test). In both patients with urticaria and control subjects, more than 99% of cutaneous 
mast cells contained tryptase and chymase. Conclusions: These data indicate that increased skin 
histamine in chronic idiopathic urticaria is not caused by increased mast cells and may 
alternatively reflect an increase in histamine content per mast cell, enhanced mast cell activation, 
or recruitment of basophils into skin in patients with chronic idiopathic urticaria. 
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Article: 
 
Chronic idiopathic urticaria is characterized by recurrent, itchy, evanescent wheals, occurring 
over a period of more than 6 weeks. Much evidence indicates a central role for cutaneous mast 
cells, although until recently, triggers of mast cell degranulation remained obscure in the 
majority of patients. More recent evidence, however, suggests that more than 50% of patients 
have circulating autoantibodies directed against IgE, the alpha subunit of the high-affinity IgE 
receptor (FcϵRI), or both molecules; these autoantibodies have functional histamine-releasing 
activity.1, 2 Others report the presence of histamine releasing factor in suction blister fluid 
overlying lesional and nonlesional skin of patients with active urticaria.3, 4 This activity may be 
related to the presence of anti-IgE or anti-FcϵRI autoantibodies in skin or may alternatively 
reflect release of chemokines, such as macrophage inflammatory protein-1α, which have been 
shown to release histamine from mast cells.5, 6 Regardless of the exact nature of the factor or 
factors responsible for mast cell mediator release, histamine remains of crucial pathogenetic 
importance in urticaria. Most patients respond to specific H1-receptor antagonists. Intradermal 
histamine exactly reproduces the symptoms (pruritus) and signs (wheal and flare) of urticaria.7 
Furthermore, increased levels of histamine have been demonstrated in nonlesional and lesional 
skin in patients with chronic idiopathic urticaria.8, 9, 10 This increase in skin histamine has been 
postulated to be due to an increase in the number of cutaneous mast cells. However, 
quantification of mast cells in vivo is complicated by the tendency of the cells to degranulate, 
such that their characteristic metachromatic staining is diminished or lost. Specific monoclonal 
antibodies to mast cell tryptase and chymase, suitable for use in immunohistochemical 
techniques, have recently become available11 and afford a high degree of specificity and 
sensitivity for mast cell detection. These antibodies were therefore used to assess mast cell 
numbers in nonlesional and lesional skin in patients with chronic idiopathic urticaria and in skin 
from healthy control subjects to investigate further the origin of observed increases in skin 
histamine in patients with urticaria. 
 
METHODS 
 
Subjects 
 
Eleven patients with chronic idiopathic urticaria were recruited (6 men and 5 women; age range, 
21 to 63 years), and nine consented to skin biopsies of both lesional and nonlesional skin. 
Chronic idiopathic urticaria was defined as the appearance of recurrent, multiple cutaneous 
wheals for more than 3 months, occurring at intervals of not less than 1 week. All patients were 
subject to a detailed history, physical examination, and as appropriate, laboratory investigation to 
exclude underlying causes of urticaria. Exclusion criteria included a history of or clinical 
evidence for predominantly physical urticarias, urticaria occurring only after ingestion of a 
specific drug or food, or clear improvement in urticaria with an additive-free and preservative-
free diet. To avoid inclusion of patients with urticarial vasculitis, patients with a history of 
wheals lasting more than 24 hours, systemic symptoms, or signs of purpura or bruising at sites of 
urticaria were excluded. Antihistamines were discontinued for 48 hours before the day of study, 
and in the case of astemizole, for 6 weeks before the study day. Ten healthy control subjects 
were also recruited (3 men and 7 women; age range, 25 to 60 years). 
 
Ethical approval 
 
All studies performed were approved by the Guy's Hospital Ethics Committee and involved 
subjects who had given informed, written consent. 
 
Skin biopsy 
 
Patients with urticaria underwent skin biopsy of an urticarial wheal within 12 hours of its 
appearance. Site-matched nonlesional skin (not subject to recent whealing) and healthy skin were 
also biopsied in patients and healthy control subjects, respectively. With the exception of two 
lesional biopsy specimens from patients with urticaria, all biopsy specimens were taken from the 
arm. Elliptical skin biopsies were performed after infiltration around but not into the biopsy site 
with local anaesthetic (1% lidocaine without epinephrine), fixed in Carnoy's fixative (methanol-
chloroform-acetic acid, 60:30:10, vol/vol) overnight, and processed in paraffin. 
 
Immunohistochemistry 
 
Tissue sections (4 μm) were mounted on glass slides and dried. Sections were dewaxed in xylene 
over three 5-minute periods and rehydrated with graded ethanol (100%, 95%, 80%, 70%, 50%) 
and water, each for a 3-minute period. Endogenous peroxidase was inhibited by incubating the 
sections in methanol containing 0.6% hydrogen peroxide for 30 minutes. Nonspecific staining 
was reduced by incubating sections with 10% heat-inactivated normal goat serum for 1 hour at 
22° C. Sections were washed with Tris-buffered saline, pH 7.4, for 5 minutes and then incubated 
with biotinylated monoclonal murine anti-chymase antibody (B7, 4 μg/ml) at 4° C overnight. 
Sections were washed with Tris-buffered saline and peroxidase-conjugated streptavidin (1:50, 
vol/vol dilution), applied for 1 hour at room temperature.11 The peroxidase reaction was 
visualized with freshly made 3-amino-9-ethylcarbazole (0.2 mg/ml in 0.1 mol/L, pH 5.2, acetate 
buffer) containing 0.01% hydrogen peroxide applied for 5 minutes. Chymase-positive mast cells 
stained a reddish brown color. Sections were washed, and alkaline phosphatase–conjugated 
murine monoclonal anti-tryptase antibody (G3AP, 1.5 μg/ml) was then applied overnight at 4° C. 
Immunostaining was visualized with fast blue RR chromogen made up as follows: 0.2 mol/L 
Tris-HCl, pH 8.2 (9.8 ml), was added to naphthol ASMX phosphate (2 mg in 0.2 ml 
dimethylformamide), followed by fast blue RR salt (10 mg). The solution was immediately 
filtered and applied to each section for 15 minutes. A blue color alone developed in mast cells 
containing tryptase MCT cells only; these were previously unstained by the anti-chymase 
antibody. Sections were then thoroughly washed with Tris-buffered saline pH 7.4, and mounted 
in aqueous medium containing 90% glycerol in phosphate-buffered saline, pH 7.4. Controls 
included omission of primary antibody and use of an IgG monoclonal antibody (MOPC315) of 
irrelevant specificity. In addition, double-labeling immunohistochemistry of sections from 
normal human lung, tonsil, and intestine was performed concurrently with skin samples as 
controls for mast cells containing tryptase and chymase (MCTC) and MCT cells. 
 
Quantification 
 
Sections were coded and read in blinded fashion by one investigator. Mast cells were counted 
under light microscopy at •160 magnification. Mast cell concentrations were obtained with using 
a Zeiss Videoplan apparatus (Carl Zeiss Inc., Thornwood, N.Y.) and calculated according to the 
following formula: mast cells/mm3 = [mast cells/mm2] • [9.5 μm + 4 μm], where 9.5 μm 
represents the mean mast cell diameter and 4 μm represents the tissue section thickness. Mast 
cell numbers were quantified in two areas of dermis (1) 0 to 183 μm and (2) 183 to 366 μm from 
the dermo-epidermal junction. Percentages of MCTC and MCT cells were also calculated. 
 
Statistics 
 
Differences in mast cell number among lesional, nonlesional, and control skin for each area 
counted (i.e., 0 to 183 μm and 183 to 366 μm) were calculated by using Student's unpaired t test. 
 
RESULTS 
 
No significant differences were observed among lesional, nonlesional, or control skin at either 0 
to 183 μm or 183 to 366 μm from the dermo-epidermal junction (Table I, Fig. 1). With the 
exception of samples from two patients with urticaria (in which 95% and 96% of mast cells, 
respectively, were of the MCTC type in nonlesional skin), in other samples (from both patients 
with urticaria and control subjects) more than 99% of mast cells present were of the MCTC type. 
 
TABLE I. Mast cell numbers in lesional, nonlesional, and control skin 
Depth from dermo-epidermal junction Lesional (n = 11) Nonlesional (n = 9) Control (n = 10) 
Depth = 0 to 186 μm 
 Range 3,888-13,690 3,901-15,358 4,234-14,483 
 Median 8,489 8,693 10,584 
 Mean (±SEM) 9,299 ± 1,009 9,018 ± 1,096 10,735 ± 900 
Depth = 186 to 366 μm 
 Range 2,345-9,640 4,941-11,567 5,377-8,920 
 Median 5,599 6,426 6,377 
 Mean ± SEM 6,044 ± 661 6,597 ± 682 6,782 ± 420  
Figures denote mast cell numbers per cubic millimeter. No significant differences were observed among any of the 
groups examined (Student's t test, p > 0.1) 
 
 
FIGURE 1. Scatter plot showing paired data points from lesional (□) and nonlesional (▵) skin, 
together with data points from skin of healthy control subjects (○) 0-183 μm and 183 to 366 μm 
from the dermo-epidermal junction. No significant differences were observed between these 
groups (Student's unpaired t test). 
 
DISCUSSION 
 
Chymase and tryptase are located almost exclusively in mast cells, basophils containing 
negligible amounts of tryptase (0.04 pg/cell) and undetectable amounts of chymase. The alkaline 
phosphatase–conjugated G3 antibody stains only mast cells.11 Similarly, eosinophils, neutrophils, 
monocytes, and lymphocytes have no detectable tryptase.12, 13 Thus immunohistochemical 
localization of these two enzymes provides a discriminating marker for human mast cells. 
Although chymase and tryptase are released during degranulation of allergen-stimulated mast 
cells, mast cells remain immunohistochemically detectable with this method because they are not 
completely depleted of their protease content and perhaps because a portion of the released 
proteases remain closely associated with the cells (Schwartz LB, Irani AA. Unpublished data). 
 
The data indicate that the numbers of mast cells in nonlesional and control skin are similar and 
are in agreement with the findings of a previous study in which mast cell numbers were 
quantified with toluidine blue.14 The finding that numbers of mast cells in lesional skin are 
comparable to those in control and nonlesional skin contrasts with the previously reported 
finding that a 10-fold increase in mast cells was observed in lesional urticarial skin.15 This latter 
study, however, used Leder's chloracetate esterase reaction for mast cell detection,16which stains 
neutrophils in addition to mast cells. Hence, in the presence of neutrophilic infiltrates, which are 
well-documented in urticarial lesions,15, 17, 18, 19 mast cell numbers may be overestimated,20 thus 
accounting for the discrepancy. 
 
Observed increases in nonlesional and lesional skin histamine content cannot therefore, on the 
basis of current data, be explained by an increase in the number of mast cells. The increase in 
lesional skin histamine may be due to recruitment of basophils into skin, as has been 
demonstrated in the late-phase cutaneous reaction to antigen with the skin chamber 
model.21 Others,15 however, found no histologic evidence of basophils in lesional chronic 
urticaria, although it is possible that once recruited to extravascular sites, basophils degranulate 
too rapidly to be distinguished morphologically. To date, no basophil-specific epitopes have been 
identified, which would allow more definitive quantification of tissue basophils in urticaria. 
Alternatively, production of histamine by mast cells may be generally increased in urticaria 
because of repeated mast cell degranulation and histamine release, possibly resulting in induction 
of histidine decarboxylase and greater histamine content per mast cell. This phenomenon might 
also account for the putative increases in nonlesional skin histamine, when amounts released 
could be subclinical. 
 
Normal skin has been previously reported to contain MCTC cells exclusively, and thus the current 
finding that more than 99% of skin mast cells are MCTC cells in healthy control subjects is 
expected. In systemic mastocytosis MCTC cells again are the predominant type of mast cells 
present.22 The majority of cutaneous mast cells in patients with chronic idiopathic urticaria 
similarly demonstrated the MCTCphenotype. This observation may have functional significance 
in urticaria, given the susceptibility of skin MCTC cells to activation by neuropeptides such as 
substance P.23, 24, 25, 26 
 
In conclusion, when a specific, sensitive double-labeling immunohistochemical technique is 
used, mast cell numbers in nonlesional and lesional skin from patients with chronic idiopathic 
urticaria are similar to those of control subjects. These data suggest that previously documented 
increases in skin histamine in patients with urticaria are unlikely to be due to a change in 
numbers of skin mast cells and may alternatively reflect an increased histamine content per mast 
cell, an increased activation state of the mast cells, or recruitment of basophils into the skin. 
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